Why Are Researchers Trying To Change Adult Stem Cells Into Embryonic Stem Cells?
P T. 2014 Dec; 39(12): 846-847, 854-857.
Stem Prison cell Therapy: a Look at Current Research, Regulations, and Remaining Hurdles
In September 2014, the Sanford Stem Cell Clinical Heart at the University of California, San Diego (UCSD) Health Organization announced the launch of a groundbreaking clinical trial to assess the safety of neural stem prison cell–based therapy in patients with chronic spinal cord injury. Researchers hope that the transplanted stalk cells will develop into new neurons that replace severed or lost nerve connections and restore at least some motor and sensory function.1
2 boosted clinical trials at UCSD are testing stem cell–derived therapy for type-1 diabetes and chronic lymphocytic leukemia, the well-nigh common form of claret cancer.1
These three studies are significant in that they are among the first efforts in stalk cell research to make the leap from laboratory to homo clinical trials. While the number of patients involved in each written report is small, researchers are optimistic that as these trials progress and additional trials are launched, a greater number of patients will exist enrolled. UCSD reports that trials for eye failure, amyotrophic lateral sclerosis, and incomprehension are in planning stages.1
The study of stalk cells offers great promise for better understanding basic mechanisms of man development, besides every bit the hope of harnessing these cells to care for a wide range of diseases and weather condition.2 However, stem jail cell research— particularly human embryonic stem prison cell (hESC) research, which involves the destruction of days-sometime embryos—has besides been a source of ongoing ethical, religious, and political controversy.2
The Politics of Progress
In 1973, the Department of Health, Instruction, and Welfare (now the Department of Wellness and Human Services) placed a moratorium on federally funded research using live human embryos.3 , iv In 1974, Congress adopted a similar moratorium, explicitly including in the ban embryos created through in vitro fertilization (IVF). In 1992, President George H.Westward. Bush-league vetoed legislation to elevator the ban, and in 2001, President George Due west. Bush issued an executive order banning federal funding on stalk cells created after that fourth dimension.3 , 4 Some states, withal, have permitted their limited use. New Jersey, for example, allows the harvesting of stem cells from cloned human embryos, whereas several other states prohibit the creation or devastation of any man embryos for medical inquiry.iii , four
In 2009, presently subsequently taking role, President Barack Obama lifted the eight-twelvemonth-old ban on federally funded stem jail cell research, allowing scientists to brainstorm using existing stalk jail cell lines produced from embryos left over afterward IVF procedures.5 (A stalk jail cell line is a group of identical stem cells that can be grown and multiplied indefinitely.)
The National Institutes of Health (NIH) Human being Embryonic Stem Cell Registry6 lists the hESCs eligible for utilize in NIH-funded inquiry. At this writing, 283 eligible lines met the NIH'southward strict ethical guidelines for human stalk prison cell research pertaining to the embryo donation process.7 For case, to get a human embryonic stem cell line approved, grant applicants must show that the embryos were "donated past individuals who sought reproductive treatment and who gave voluntary written consent for the human embryos to exist used for research purposes." 8 The ESCs used in enquiry are not derived from eggs fertilized in a woman's body.9
Because of the separate legislative ban, it is however not possible for researchers to create new hESC lines from viable embryos using federal funds. Federal money may, however, exist used to inquiry lines that were derived using private or state sources of funding.5
While funding restrictions and political debates may have slowed the grade of stem cell inquiry in the Usa,10 the field continues to evolve. This is evidenced by the large number of studies published each year in scientific journals on a wide range of potential uses beyond a variety of therapeutic areas.11 – xiii
The Food and Drug Assistants (FDA) has approved numerous stem jail cell–based treatments for clinical trials. A 2013 report from the Pharmaceutical Research and Manufacturers of America lists 69 cell therapies every bit having clinical trials under review with the FDA, including fifteen in phase 3 trials. The therapeutic categories represented in these trials include cardiovascular disease, skin diseases, cancer and related conditions, digestive disorders, transplantation, genetic disorders, musculoskeletal disorders, and eye weather condition, amid others.fourteen
Nonetheless, the earliest stem cell therapies are likely years away. To appointment, the only stem jail cell–based handling approved past the FDA for use in this country is for bone marrow transplantation.15 As of 2010 (the latest year for which information are bachelor), more than 17,000 blood cancer patients had had successful stalk jail cell transplants.sixteen
A Brief Stem Prison cell Timeline
Research on stem cells began in the tardily 19th century in Europe. German biologist Ernst Haeckel coined the term stem jail cell to depict the fertilized egg that becomes an organism.17
In the U.S., the study of adult stem cells took off in the 1950s when Leroy C. Stevens, a cancer researcher based in Bar Harbor, Maine, found large tumors in the scrotums of mice that contained mixtures of differentiated and undifferentiated cells, including hair, bone, abdominal, and claret tissue. Stevens and his team concluded that the cells were pluripotent, pregnant they could differentiate into any cell constitute in a fully grown beast. Stem jail cell scientists are using that carefully documented enquiry today.17
In 1968, Robert A. Good, MD, PhD, at the University of Minnesota, performed the first successful os marrow transplant on a child suffering from an immune deficiency. Scientists later discovered how to derive ESCs from mouse embryos and in 1998 developed a method to accept stalk cells from a homo embryo and grow them in a laboratory.17
Why Stem Cells?
Many degenerative and currently untreatable diseases in humans arise from the loss or malfunction of specific jail cell types in the trunk.ix While donated organs and tissues are ofttimes used to replace damaged or dysfunctional ones, the supply of donors does non meet the clinical demand.18 Stem cells seemingly provide a renewable source of replacement cells and tissues for transplantation and the potential to treat a myriad of conditions.
Stem cells accept two of import and unique characteristics: Start, they are unspecialized and capable of renewing themselves through cell division. When a stem cell divides, each new cell has the potential either to remain a stem cell or to differentiate into other kinds of cells that form the body'south tissues and organs. Stem cells can theoretically split up without limit to replenish other cells that have been damaged.9
Second, nether certain controlled weather condition, stem cells tin can exist induced to become tissue- or organ-specific cells with special functions. They tin can then be used to treat diseases affecting those specific organs and tissues. While bone marrow and gut stem cells dissever continuously throughout life, stem cells in the pancreas and middle carve up only under appropriate conditions.ix
Embryonic Versus Adult Stem Cells
In that location are two main types of stem cells: one) embryonic stem cells (ESCs), constitute in the embryo at very early stages of evolution; and 2) somatic or adult stem cells (ASCs), institute in specific tissues throughout the trunk later development.9
The advantage of embryonic stalk cells is that they are pluripotent—they can develop into any of the more than 200 cell types plant in the trunk, providing the potential for a broad range of therapeutic applications. Adult stalk cells, on the other manus, are idea to exist limited to differentiating into different cell types of their tissue of origin.9 Blood cells, for instance, which come from adult stem cells in the os marrow, can specialize into red claret cells, but they will non become other cells, such as neurons or liver cells.
A significant reward of developed stem cells is that they offer the potential for autologous stem cell donation. In autologous transplants, recipients receive their own stem cells, reducing the risk of immune rejection and complications. Additionally, ASCs are relatively free of the ethical issues associated with embryonic stem cells and have go widely used in research.
Induced Pluripotent Stalk Cells
Representing a relatively new expanse of research, induced pluripotent stem cells (iPSCs) are developed stem cells that have been genetically reprogrammed dorsum to an embryonic stem cell–like state. The reprogrammed cells function similarly to ESCs, with the ability to differentiate into any prison cell of the torso and to create an unlimited source of cells. So iPSCs have meaning implications for illness inquiry and drug development.
Pioneered by Japanese researchers in 2006, iPSC technology involves forcing an developed cell, such as a peel, liver, or stomach cell, to express proteins that are essential to the embryonic stalk jail cell identity. The iPSC technology not only bypasses the need for human embryos, avoiding ethical objections, but also allows for the generation of pluripotent cells that are genetically identical to the patient'south. Like adult cells, these unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection.9
In 2013, researchers at the Spanish National Cancer Research Heart in Madrid successfully reprogrammed adult cells in mice, creating stem cells that can grow into any tissue in the body. Prior to this written report, iPSCs had never been grown outside Petri dishes in laboratories.19 And, in July 2013, Japan'southward wellness government minister approved the first use of iPSCs in human trials. The Riken Middle for Developmental Biology will use the cells to attempt to treat age-related macular degeneration, a common cause of blindness in older people. The small-calibration pilot study would test the safety of iPSCs transplanted into patients' eyes.xx
The Promise of iPSCs
According to David Owens, PhD, Program Director of the Neuroscience Centre at NIH's National Institute of Neurological Disorders and Stroke (NINDS), one of the fundamental hurdles to using stem cells to care for disease is that scientists practice non still fully empathize the diseases themselves, that is, the genetic and molecular signals that direct the aberrant cell sectionalization and differentiation that cause a particular condition. "You desire that before you suggest a therapeutic," he says, "because yous want a business firm, rational basis for what you're trying to do, what y'all're trying to modify."
Although well-nigh of the media attending effectually stem cells has focused on regenerative medicine and cell therapy, researchers are finding that iPSCs, in particular, hold significant promise equally tools for disease modeling.21 , 22 A major barrier to enquiry is ofttimes inaccessibility of diseased tissue for written report.23 Considering iPSCs can be derived direct from patients with a given affliction, they display all of the molecular characteristics associated with the illness, thereby serving as useful models for the study of pathological mechanisms.
"The biggest payoff early on will be using these cells as a tool to understand the disease improve," says Dr. Owens. For instance, he explains that creating dopamine neurons from iPSC lines could aid scientists more than closely report the mechanisms behind Parkinson's disease. "If we get a ameliorate handle on the disorders themselves, then that will as well help us generate new therapeutic targets." Recent studies testify the utilize of these patient-specific cells to model other neurodegenerative disorders, including Alzheimer's and Huntington'southward diseases.24 – 26
In improver to using iPSC engineering, it is as well possible to derive patient-specific stem cell lines using an arroyo called somatic jail cell nuclear transfer (SCNT). This process involves adding the nuclei of adult skin cells to unfertilized donor oocytes. As reported in spring 2014, a team of scientists from the New York Stem Cell Foundation Research Institute and Columbia University Medical Center used SCNT to create the first disease-specific embryonic stem prison cell line from a patient with type-1 diabetes. The insulin-producing cells have two sets of chromosomes (the normal number in humans) and could potentially be used to develop personalized jail cell therapies.27
Many Hurdles Ahead
The evolution of iPSCs and related technologies may aid address the ethical concerns and open up new possibilities for studying and treating disease, simply there are nonetheless barriers to overcome. One major obstacle is the tendency of iPSCs to grade tumors in vivo. Using viruses to genomically alter the cells can trigger the expression of cancer-causing genes, or oncogenes.28
Much more research is needed to empathise the total nature and potential of stem cells as future medical therapies. It is not known, for example, how many kinds of adult stem cells exist or how they evolve and are maintained.9
Some of the challenges are technical, Dr. Owens explains. For example, generating big enough numbers of a cell type to provide the amounts needed for treatment is hard. Some developed stem cells have a very express ability to divide, making it difficult to multiply them in large numbers. Embryonic stalk cells grow more quickly and easily in the laboratory. This is an important distinction because stalk cell replacement therapies require large numbers of cells.29
Likewise, says Dr. Owens, stem jail cell transplants present immunological hurdles: "If you do introduce cells into a tissue, volition they be rejected if they're not autologous cells? Or, you might accept immunosuppression with the private who received the cells, and then there are additional complications involved with that. That'southward still non entirely clear."
Such safety issues need to exist addressed earlier any new stem prison cell–based therapy tin advance to clinical trials with real patients. Co-ordinate to Dr. Owens, the preclinical testing stage typically takes most 5 years. This would include assessment of toxicity, tumorigenicity, and immunogenicity of the cells in treating animal models for disease.30
"Those are things we have to continually learn near and try to address. It volition take fourth dimension to sympathise them better," Dr. Owens says. Asked nearly the importance of collaboration in overcoming the scientific, regulatory, and financial challenges that lie ahead, he says, "It's unlikely that ane entity could do it all alone. Collaboration is essential."
Research and Clinical Trials
Ultimately, stem cells have huge therapeutic potential, and numerous studies are in progress at academic institutions and biotechnology companies around the country. Studies at the NIH bridge multiple disciplines, notes Dr. Owens, who oversees funding for stem cell research at NINDS. (Figure 1 shows the recent history of NIH funding for stem jail cell research.) He describes one area of considerable involvement as the promotion of regeneration in the brain based on endogenous stem cells. Until recently, it was believed that adult brain cells could not exist replaced. Notwithstanding, the discovery of neurogenesis in bird brains in the 1980s led to startling evidence of neural stalk cells in the human brain, raising new possibilities for treating neurodegenerative disorders and spinal cord injuries.31
"It's a fascinating idea," says Dr. Owens. "It'south unclear nonetheless what the functions of those cells are. They could probably play different roles in dissimilar species, but only the fundamental properties themselves are very interesting." He cites a number of NINDS-funded studies looking at those basic properties.
In another NIH-funded report, Advanced Prison cell Applied science (Human activity), a Massachusetts-based biotechnology company, is testing the safe of hESC-derived retinal cells to care for patients with an heart disease called Stargardt's macular dystrophy. A second ACT trial is testing the safe of hESC-derived retinal cells to treat age-related macular degeneration patients.32 , 33
In Apr 2014, scientists at the Academy of Washington reported that they had successfully regenerated damaged heart muscles in monkeys using heart cells created from hESCs. The inquiry, published in the journal Nature, was the first to show that hESCs can fully integrate into normal heart tissue.34
The study did not answer every question and had its complications—it failed to show whether the transplanted cells improved the function of the monkeys' hearts, and some of the monkeys developed arrhythmias.34 , 35 Nonetheless, the researchers are optimistic that it will pave the mode for a man trial earlier the stop of the decade and lead to meaning advances in treating eye affliction.29
In May 2014, Asterias Biotherapeutics, a California-based biotechnology company focused on regenerative medicine, announced the results of a phase 1 clinical trial assessing the safe of its product AST-OPC1 in patients with spinal cord injuries.36 The study represents the first-in-human trial of a cell therapy derived from hESCs. Results prove that all five subjects have had no serious adverse events associated with the administration of the cells, with the AST-OPC1 itself, or with the immunosuppressive regimen. A phase 1/2a dose-escalation report of AST-OPC1 in patients with spinal string injuries is awaiting approval from the FDA.37
The FDA itself has a team of scientists studying the potential of mesenchymal stem cells (MSCs), adult stem cells traditionally found in the os marrow. Multipotent stem cells, MSCs differentiate to form cartilage, bone, and fat and could be used to repair, supercede, restore, or regenerate cells, including those needed for heart and bone repair.38
Publicly available information about federally and privately funded clinical research studies involving stalk cells tin can exist establish at http://clinicaltrials.gov. However, the FDA cautions that the data provided on that site is supplied by the production sponsors and is not reviewed or confirmed by the bureau.
"The biggest payoff early on on volition be using these cells as a tool to understand the disease better. If we get a better handle on the disorders themselves, and so that will also help us generate new therapeutic targets."
—David Owens, PhD, Program Director, Neuroscience Middle, National Plant of Neurological Disorders and Stroke
Global Research Efforts
Stem cell inquiry policy varies significantly throughout the earth every bit countries grapple with the scientific and social implications. In the Eu, for instance, stalk cell research using the homo embryo is permitted in Belgium, United kingdom, Denmark, Republic of finland, Greece, the Netherlands, and Sweden; even so, it is illegal in Austria, Germany, Republic of ireland, Italy, and Portugal.39
In those countries where cell lines are accessible, research continues to create an array of scientific advances and widen the scope of stalk cell application in human diseases, disorders, and injuries. For example, in February 2014, Cellular Biomedicine Group, a China-based company, released the six-month follow-up data analysis of its phase 1/2a clinical trial for ReJoin, a human adipose-derived mesenchymal forerunner cell (haMPC) therapy for genu osteoarthritis. The study, which tested the safety and efficacy of intra-articular injections of autologous haMPCs to reduce inflammation and repair damaged articulation cartilage, showed knee pain was significantly reduced and human knee mobility was improved.40 And the periodical Stem Jail cell Enquiry & Therapy reported that researchers at the University of Adelaide in Commonwealth of australia recently completed a projection showing stem cells taken from teeth could class "complex networks of brain-similar cells." Although the cells did not abound into full neurons, the researchers say that it will happen given time and the right atmospheric condition.41
The Regulation of Stalk Cells
In February 2014, the U.S. Court of Appeals for the District of Columbia Circuit upheld a 2012 ruling that a patient'southward stem cells for therapeutic utilise autumn under the aegis of the FDA.42 The appeals case involved the company Regenerative Sciences, which was using patients' MSCs in its Regenexx procedure to care for orthopedic problems.43
The FDA'due south Middle for Biologics Evaluation and Inquiry (CBER) regulates human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion, or transfer into a human recipient, including hematopoietic stem cells. Under the authority of Section 361 of the Public Health Service Act, the FDA has established regulations for all HCT/Ps to prevent the transmission of infectious disease.44
The Regenexx case highlights an ongoing fence almost whether autologous MSCs are biological drugs subject to FDA approval or only homo cellular and tissue products. Some medical centers collect, concentrate, and reinject MSCs into a patient to treat osteoarthritis merely practise not add other agents to the injection. The FDA contends that any process that includes culturing, expansion, and added growth factors or antibiotics requires regulation considering the process constitutes pregnant manipulation. Regenerexx has countered that the process does not involve the development of a new drug, which could be given to a number of patients, merely rather a patient's own MSCs, which affects just that ane patient.
Ensuring the safe and efficacy of stem cell–based products is a major challenge, says the FDA. Cells manufactured in large quantities exterior their natural environs in the human trunk can potentially become ineffective or dangerous and produce significant adverse effects such every bit tumors, astringent allowed reactions, or growth of unwanted tissue. Even stem cells isolated from a person'southward own tissue tin potentially present these risks when put into an expanse of the trunk where they could not perform the same biological part that they were originally performing. Stem cells are immensely circuitous, the FDA cautions—far more and then than many other FDA-regulated products—and they bring with them unique considerations for meeting regulatory standards.
To engagement, no U.S. companies have received FDA approval for any autologous MSC therapy, although a study is ongoing to appraise the feasibility and condom of autologous MSCs for osteoarthritis.45 One of the major risks with MSCs is that they could potentially pb to cancer or differentiation into bone or cartilage.46
What'south Adjacent
The numerous stalk cell studies in progress across the globe are just a start step on the long route toward eventual therapies for degenerative and life-ending diseases. Because of their unlimited ability to self-renew and to differentiate, embryonic stalk cells remain, theoretically, a potential source for regenerative medicine and tissue replacement after injury or disease. However, the difficulty of producing large quantities of stem cells and their tendency to class tumors when transplanted are just a few of the formidable hurdles that researchers still face. In the meantime, the shorter-term payoff of using these cells equally a tool to better sympathize diseases has significant implications.
Social and ethical issues around the use of embryonic stem cells must also be addressed. Many nations, including the U.S., have government-imposed restrictions on either embryonic stem cell inquiry or the production of new embryonic stalk prison cell lines. Induced pluripotent stem cells offering new opportunities for development of cell-based therapies while also providing a way effectually the ethical dilemma of using embryos, just just how skilful an alternative they are to embryonic cells remains to be seen.
It is clear that many challenges must exist overcome earlier stem cells tin be safely, finer, and routinely used in the clinical setting. However, their potential benefits are numerous and concord tremendous promise for an assortment of new therapies and treatments.
Acknowledgments
The authors wish to thank the FDA staff for their back up in writing this article and Rachael Conklin, Consumer Safe Officer, Consumer Affairs Branch, Division of Communication and Consumer Affairs, Middle for Biologics Evaluation and Research, for her help in organizing the comments provided by FDA staff.
REFERENCES
ane. University of California, San Diego Wellness Sciences. With three offset-in-human being trials, therapeutic stalk cell science takes a assuming step. ScienceDaily. Oct twenty, 2014. Available at: http://www.sciencedaily.com/releases/2014/10/141020141535.htm. Accessed October 28, 2014.
iii. Wertz DC. Embryo and stem cell research in the United States: history and politics. Factor Therapy. 2002;ix(xi):674–678. [PubMed] [Google Scholar]
four. Boonstra H. 1974 National Research Act. Human embryo and fetal enquiry: medical support and political controversy. The Guttmacher Written report on Public Policy. 2001;four(one):iii–5. [Google Scholar]
5. Murugan V. Embryonic stem prison cell research: a decade of debate from Bush to Obama. Yale J Biol Med. 2009;82(3):101–103. [PMC complimentary article] [PubMed] [Google Scholar]
10. Claiborn K. Federal funding for stem cell research: 15 years of indecision. J Clin Invest. 2011;121(seven):2531. [PMC free article] [PubMed] [Google Scholar]
eleven. Martinez Hour, Molina-Lopez JF, Gonzalez-Garza MT, et al. Stem jail cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, prophylactic, and feasibility. Jail cell Transplant. 2012;21(9):1899–1907. [PubMed] [Google Scholar]
12. Purandare C, Shitole DG, Belle V, et al. Therapeutic potential of autologous stem cell transplantation for cerebral palsy. Instance Rep Transplant. 2012;2012:825289. [PMC free article] [PubMed] [Google Scholar]
thirteen. Bhasin A, Padma Srivastava MV, Mohanty S, et al. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2012;115(7):1003–1008. [PubMed] [Google Scholar]
xviii. Cascalho One thousand, Ogle BM, Platt JL. The future of organ transplantation. Ann Transplant. 2006;11(ii):44–47. [PubMed] [Google Scholar]
20. Riken Center for Developmental Biology. Airplane pilot clinical study into iPS cell therapy for eye illness starts in Japan. Jul, 2013. Available at: http://world wide web.riken.jp/en/pr/press/2013/20130730_1. Accessed August 19, 2014.
21. Ebert AD, Liang P, Wu JC. Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol. 2012;60(4):408–416. [PMC free commodity] [PubMed] [Google Scholar]
22. Immature West, D'Souza SL, Lemischka IR, Schaniel C. Patient-specific induced pluripotent stem cells every bit a platform for affliction modeling, drug discovery and precision personalized medicine. J Stalk Cell Res Ther. 2012:S10:010. doi: 10.4172/2157-7633.S10-010. [CrossRef] [Google Scholar]
23. Lee J, Kim Y, Yi H, et al. Generation of illness-specific induced pluripotent stalk cells from patients with rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2014;16(1):R41. doi: 10.1186/ar4470. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Wang H, Doering LC. Induced pluripotent stalk cells to model and treat neurogenetic disorders. Neural Plast. 2012;2012:346053. doi: ten.1155/2012/346053. [PMC costless article] [PubMed] [CrossRef] [Google Scholar]
25. Jeon I, Choi C, Lee N, et al. In vivo roles of a patient-derived induced pluripotent stem cell line (HD72-iPSC) in the YAC128 model of Huntington's disease. Int J Stalk Cells. 2014;7(1):43–47. [PMC free commodity] [PubMed] [Google Scholar]
26. Byers B, Lee HL, Reijo Pera R. Modeling Parkinson's disease using induced pluripotent stem cells. Curr Neurol Neurosci Rep. 2012;12(3):237–242. [PMC complimentary article] [PubMed] [Google Scholar]
27. Yamada M, Johannesson B, Sagi I, et al. Human oocytes reprogram adult somatic nuclei of a blazon 1 diabetic to diploid pluripotent stem cells. Nature. 2014;510(7506):533–536. [PubMed] [Google Scholar]
28. Lee Equally, Tang C, Rao MS, et al. Tumorigenicity every bit a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;nineteen(eight):998–1004. [PMC free article] [PubMed] [Google Scholar]
30. Goldring CEP, Duffy PA, Benvenisty N, et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell. 2011;eight(six):618–628. [PubMed] [Google Scholar]
34. Chong JJH, Yang X, Don CW, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510(7504):273–277. [PMC costless commodity] [PubMed] [Google Scholar]
35. Abbott A. Doubts over heart stem-cell therapy. Nature. 2014;509(7498):xv–16. [PubMed] [Google Scholar]
39. Pompe South, Bader M, Tannert C. Stalk-cell inquiry: the country of the art. EMBO Rep. 2005;6(4):297–300. [PMC free commodity] [PubMed] [Google Scholar]
forty. Cellular Biomedicine Grouping. Cellular Biomedicine Grouping releases positive half-dozen-month data from stage I/IIa clinical trial for ReJoin treatment of knee osteoarthritis (KOA) Jun, 2014. Available at: http://cellbiomedgroup.com/news-details.php?nid=42. Accessed August 24, 2014.
41. Ellis KM, O'Carroll DC, Lewis MD, et al. Neurogenic potential of dental lurid stem cells isolated from murine incisors. Stem Jail cell Res Ther. 2014;5(1):xxx. doi: 10.1186/scrt419. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
42. Grens One thousand. Judges side with FDA on stem cells. The Scientist. 2014 February 6; [Google Scholar]
43. Drabiak-Syed K. Challenging the FDA's potency to regulate autologous adult stem cells for therapeutic use: Celltex therapeutics' partnership with RNL Bio, substantial medical risks, and the implications of United States v. Regenerative Sciences. Health Matrix Clevel. 2013;23(2):493–535. [PubMed] [Google Scholar]
46. McLean K, 1, Gong Y, Choi Y, et al. Man ovarian carcinoma–associated mesenchymal stalk cells regulate cancer stem cells and tumorigenesis via altered BMP product. J Clin Invest. 2011;121(viii):3206–3219. [PMC free article] [PubMed] [Google Scholar]
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264671/
Posted by: tomlinsonpards1941.blogspot.com
0 Response to "Why Are Researchers Trying To Change Adult Stem Cells Into Embryonic Stem Cells?"
Post a Comment